First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa

References

• Khan F, Tritschler T, Kahn SR, et al. Venous thromboembolism. Lancet. 2021 Jul 3;398(10294):64–77. doi: 10.1016/S0140-6736(20)32658-1
   PubMed Web of Science ®Google Scholar
• Heestermans M, Poenou G, Hamzeh-Cognasse H, et al. Anticoagulants: a short history, their mechanism of action, pharmacology, and indications. Cells. 2022 Oct 13;11(20):3214. doi: 10.3390/cells11203214
   PubMed Web of Science ®Google Scholar
• Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007 Sep;83(983):575–582. doi: 10.1136/pgmj.2007.059188
   PubMed Web of Science ®Google Scholar
• PS W, AM H, NR C, et al. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–683. doi: 10.7326/0003-4819-121-9-199411010-00009
   PubMed Web of Science ®Google Scholar
• Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–1776. doi: 10.1016/S0140-6736(20)32439-9
   PubMed Web of Science ®Google Scholar
• Gomez-Outes A, Garcia-Fuentes M, Suarez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195–1205. doi: 10.1080/17460441.2017.1384811
   PubMed Web of Science ®Google Scholar
• Meneyrol J, Follmann M, Lassalle G, et al. 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperaz in-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor. J Med Chem. 2013 Dec 12;56(23):9441–9456. doi: 10.1021/jm4005835
   PubMed Web of Science ®Google Scholar
• Hummel J, McKendrick S, Brindley C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009 Jan;8(1):38–49. doi: 10.1002/pst.326
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Meibohm B, Weiner D. Pattern recognition in pharmacokinetic data analysis. AAPS J. 2016 Jan;18(1):47–63. doi: 10.1208/s12248-015-9817-6
   PubMed Web of Science ®Google Scholar
• Noe DA. Parameter estimation and reporting in noncompartmental analysis of clinical pharmacokinetic data. Clin Pharmacol Drug Dev. 2020 Jul;9(1):S5–S35. doi: 10.1002/cpdd.810
   PubMedGoogle Scholar
• Remko M, Remkova A, Broer R. Theoretical study of molecular structure and physicochemical properties of novel factor Xa inhibitors and dual factor Xa and factor IIa inhibitors. Molecules. 2016 Feb 4;21(2):185. doi: 10.3390/molecules21020185
   PubMed Web of Science ®Google Scholar
• Tucker GT. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 1981 Dec;12(6):761–770. doi: 10.1111/j.1365-2125.1981.tb01304.x
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010 Nov;70(5):703–712. doi: 10.1111/j.1365-2125.2010.03753.x
   PubMed Web of Science ®Google Scholar
• Chong DT, Andreotti F, Verhamme P, et al. Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian pacific society of cardiology on strategies for thrombotic and bleeding risk management. Eur Cardiol. 2021 Feb;16:e23
   PubMed Web of Science ®Google Scholar
• Bozic Mijovski M. Advances in monitoring anticoagulant therapy. Adv Clin Chem. 2019;90:197–213.
   PubMed Web of Science ®Google Scholar
• Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003 Jul [2004 Aug]; 33(4):173–183. doi: 10.1159/000081505
   PubMed Web of Science ®Google Scholar
• Lind SE, Boyle ME, Fisher S, et al. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol. 2014 May;141(5):665–674. doi: 10.1309/AJCPGTCEX7K4GXQO
   PubMed Web of Science ®Google Scholar
• Blair HA, Keating GM. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. Drugs. 2017 Mar;77(3):331–344. doi: 10.1007/s40265-017-0699-z
   PubMed Web of Science ®Google Scholar
• Solbeck S, Jensen AS, Maschmann C, et al. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG((R))), hemoclot thrombin inhibitor (HTI) assay and ecarin clotting time (ECT). Scand J Clin Lab Invest. 2018 Feb;78(1–2):25–30. doi: 10.1080/00365513.2017.1408138
   PubMed Web of Science ®Google Scholar
• Maegele M, Grottke O, Schochl H, et al. Direct oral anticoagulants in emergency trauma admissions. Dtsch Arztebl Int. 2016 Sep 5;113(35–36):575–582. doi: 10.3238/arztebl.2016.0575
   PubMed Web of Science ®Google Scholar
• Graefe-Mody US EU, Rathgen K, Stähle H, et al. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006;4(7):1502–1509. doi: 10.1111/j.1538-7836.2006.02020.x
   PubMed Web of Science ®Google Scholar
• Liu YO, Xie QF, Liu ZY, et al. Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation. Front Cardiovasc Med. 2022;9:998751. doi: 10.3389/fcvm.2022.998751
   PubMed Web of Science ®Google Scholar
• RL S, CW F. Evaluation of mild bleeding disorders and easy bruising. Blood Rev. 1994;8(8):98–104. doi: 10.1016/S0268-960X(05)80014-1
   PubMedGoogle Scholar
• Valgimigli M, Gargiulo G. Activated clotting time during unfractionated heparin-supported coronary intervention: is access site the New piece of the puzzle? JACC: Cardiovasc Interv. 2018 Jun 11;11(11):1046–1049. doi: 10.1016/j.jcin.2018.02.022
   PubMed Web of Science ®Google Scholar